Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Heckmann JM et al. – Findings suggest that at critical periods during autoimmune MG, this SNP may result in inadequate DAF upregulation with consequent complement–mediated EOM damage. Susceptible individuals may benefit from anti–complement therapy in addition to immunosuppression.


Exclusive Author Commentary
Associate Professor JM Heckmann, 08/17/09

Extraocular muscles (EOMs) are commonly involved in active myasthenia gravis (MG) and most myasthenics develop fatiguable weakness of one or more EOMs, most likely at disease onset. If MG remains confined to the EOMs for a 2-year period and does not generalize, it is referred to as "ocular MG". In this report we investigated a different group of MG subjects that developed severe EOM pareses (i.e. non-fatiguable); most affected subjects developed this complication after generalized MG was diagnosed and whilst receiving standard immunosuppressive treatment. Further, in these subjects the ophthalmoparesis and ptosis did not respond to increasing prenisone treatment. Our current study results suggest that individuals who have MG and the SNP in the regulatory region of the DAF gene, may be at risk of indadequate DAF upregulation at critical periods during MG, which in turn may require additional anti-complement therapy to prevent EOM damage.

Today in Neurologic/Ophthalmic...keeping you current

Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
Therapeutic Advances in Neurological Disorders, 11/10/09

The management of allergic eye diseases in primary eye care
Contact Lens and Anterior Eye, 11/03/09

Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Archives of Neurology, 11/19/09

Today in Rheumatic/Autoimmune...keeping you current

Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09

Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/23/09

Safety of vaccination of patients with systemic lupus erythematosus
Lupus, 11/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address